Table 1.

Baseline characteristics of participants with rheumatoid arthritis in a study of the effect of methotrexate treatment on DNA methylation^*

	RAMS (n = 66)		UCSF‐RA (n = 11)
	Response (n = 36)†	No response (n = 30)‡	Response (n = 4)†	No response (n = 7)‡
Female	25 (69.4)	24 (80.0)	4 (100.0)	6 (85.7)
Age at baseline, mean ± SD years	60.13 ± 14.02	59.17 ± 15.24	61.85 ± 10.48	54.95 ± 12.05
Self‐reported race
Asian	0 (0.0)	0 (0.0)	0 (0.0)	1 (14.3)
African American	0 (0.0)	0 (0.0)	1 (25.0)	2 (28.6)
Other	0 (0.0)	0 (0.0)	0 (0.0)	2 (28.6)
White	36 (100.0)	30 (100.0)	3 (75.0)	2 (28.6)
Baseline DAS28‐CRP score, mean ± SD	4.96 ± 1.02	4.10 ± 1.30	3.83 ± 0.70	3.15 ± 1.04
Ever smoker, yes	20 (55.6)	16 (53.3)	1 (25.0)	5 (71.4)

^*Except where indicated otherwise, values are the number (%) or participants. RAMS = Rheumatoid Arthritis Medication Study; UCSF‐RA = University of California, San Francisco Rheumatoid Arthritis Study; DAS28 = Disease Activity Score in 28 joints using the C‐reactive protein level.

^†Treatment response was defined as “good” or “moderate” according to the EULAR response criteria.

^‡Treatment response was defined as “none” according to the EULAR response criteria.